Evidence map›Paper›PMID 39100715›Full record

ArticleHealth science reports2024

Decreased expression of p53 is associated with down expression of zyxin in breast cancer.

Rezvan Rostampour, Kiana Bahremand, Hossein Mohammadi, Seyed Askar Roghani, Ebrahim Shakiba, Mohammad Taghi Goodarzi, Soheila Asadi

Abstract read
In one paragraph

Article in Health science reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rezvan RostampourDepartment of Clinical Biochemistry Kermanshah University of Medical Sciences Kermanshah Iran.
Kiana BahremandNano Drug Delivery Research Center, Health Technology Institute Kermanshah University of Medical Sciences Kermanshah Iran.
Hossein MohammadiDepartment of Clinical Biochemistry Kermanshah University of Medical Sciences Kermanshah Iran.
Seyed Askar RoghaniClinical Research Development Center, Imam Reza Hospital Kermanshah University of Medical Science Kermanshah Iran.
Ebrahim ShakibaDepartment of Clinical Biochemistry Kermanshah University of Medical Sciences Kermanshah Iran.
Mohammad Taghi GoodarziDepartment of Biochemistry Shahrood Branch, Islamic Azad University Shahrood Iran.
Soheila AsadiDepartment of Clinical Biochemistry Kermanshah University of Medical Sciences Kermanshah Iran.ORCID 0000-0003-2443-9221

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Breast cancer (BC) is considered one of the most common malignant tumors leading to death in women, and genetic factors have a crucial role in BC pathogenesis. Zyxin (ZYX) is one of these factors that may be important in p53 level and function. Thus, the present work aimed to investigate the ZYX gene and protein expression in tumor tissue and matched margin tissue and its correlation with the p53 expression. Methods: In a present case-control study, 30 tumors and 30 matched margin tissues were obtained from Iran Tumor Bank/Tehran University of Medical Sciences. Real-time polymerase chain reaction and western blot analysis techniques were applied to evaluate the genes and protein expression, respectively. Results: The data showed that expression of the ZYX gene in tumor tissues significantly decreased ( Conclusion: Based on our observation, ZYX might have a tumor suppressor role and is associated with p53.

Indexed as

breast cancerp53zyxin

Identifiers

PMID39100715
PMCPMC11294437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.